Abstract
The individual results of SARS-CoV-2 serological tests measured after the first pandemic wave of 2020 cannot be directly interpreted as a probability of having been infected. Plus, these results are usually returned as a binary or ternary variable, relying on predefined cut-offs. We propose a Bayesian mixture model to estimate individual infection probabilities, based on 81,797 continuous anti-spike IgG tests from Euroimmun collected in France after the first wave. This approach used serological results as a continuous variable, and was therefore not based on diagnostic cut-offs. Cumulative incidence, which is necessary to compute infection probabilities, was estimated according to age and administrative region. In France, we found that a "negative" or a "positive" test, as classified by the manufacturer, could correspond to a probability of infection as high as 61.8% or as low as 67.7%, respectively. "Indeterminate" tests encompassed probabilities of infection ranging from 10.8 to 96.6%. Our model estimated tailored individual probabilities of SARS-CoV-2 infection based on age, region, and serological result. It can be applied in other contexts, if estimates of cumulative incidence are available.
Introduction: The Limitations of Binary Serology
Standard SARS-CoV-2 antibody tests typically rely on fixed "positive/negative" cut-offs that discard nuanced data and ignore an individual's demographic risk. For instance, the Euroimmun ELISA test measures an Optical Density Ratio (ODR) where values < 0.8 are labeled "negative" and > 1.1 are "positive." This approach suffers from significant information loss near thresholds and fails to account for "pre-test probability"—the likelihood of infection based on context like age or location. Furthermore, a significant minority of infected individuals (5–24%) are "non-responders" who produce few antibodies and are almost always misclassified by standard cut-offs.
Methodology: A Bayesian Mixture Model
To address these flaws, researchers developed a Bayesian mixture model using the SAPRIS-SERO dataset, which contains 81,797 continuous anti-spike IgG test results from French adults collected after the first pandemic wave in mid-2020.
Instead of relying on manufacturer thresholds, the model treats the population as a weighted average of two distributions: $P(\text{ELISA} | \text{infected})$ and $P(\text{ELISA} | \text{uninfected})$. The uninfected group was modeled using a skew-normal distribution to capture the data's "tail," while the infected group used a mixture of two normal distributions to account for both antibody "responders" and "non-responders."
Cumulative incidence (the weight of the infected group) was incorporated as a prior, using age and administrative region as covariates. To ensure model convergence, the researchers first calibrated the antibody distribution using a validation set of 319 RT-PCR-confirmed positive participants.
Personalized Infection Probabilities
The model's primary strength is its ability to provide personalized risk assessments. The results demonstrate that a "negative" result is not universally negative. For example, in the high-incidence Île-de-France (Paris) region, a 40-49-year-old with an ODR of 0.8—the very threshold for a negative result—actually has a 61.8% probability of past infection.
The "indeterminate" zone (0.8–1.1) was found to be a wide spectrum, representing infection probabilities ranging from 10.8% to 96.6% depending on the individual's demographic profile. The model also estimated that 14.5% of infected individuals are non-responders, explaining why traditional sensitivity estimates (often cited at >90%) are frequently over-optimistic in real-world settings.
Key Findings and Epidemiological Impact
By refining the interpretation of serological data, the model provided more accurate epidemiological estimates for France after the first wave:
- Cumulative Incidence: Estimated at 7.6% nationally, peaking at 11.7% in the Paris region.
- Test Performance: The actual sensitivity for the 1.1 cut-off was 75.9%, significantly lower than manufacturer claims, though specificity remained near 100%.
- Severity Metrics: The overall Infection Fatality Rate (IFR) was estimated at 0.8%, but this was heavily skewed by age, reaching 21.6% for those 80 and older. Similarly, the Infection Hospitalization Rate (IHR) for the 80+ demographic was 33.7%.
Limitations and Future Directions
While powerful, the model has limitations. The "infected" distribution was calibrated using RT-PCR positive individuals, who are typically symptomatic; asymptomatic individuals might have lower antibody levels, potentially leading to an underestimate of the non-responder rate. Additionally, the study focused on a specific 9-month window; applying this model to longer-term data would require incorporating antibody waning functions. Despite these factors, the continuous Bayesian approach provides a more robust framework for interpreting serological results than traditional binary classification.
Summary updated